- Catalog number
- ICH5026-100mg
- Size / count
- 100 mg
- Dry ice
- No
- Hazardous
- No
- Discontinued
- No
- Background
- ichorbio’s Mosunetuzumab biosimilar is a bispecific, humanized monoclonal antibody with potential antineoplastic activity. Anti-CD20/CD3 bispecific monoclonal antibody BTCT4465A contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, BTCT4465A binds to both T cells and CD20-expressing tumor B cells; this cross-links T cells to tumor cells, and may result in a potent cytotoxic T-lymphocyte (CTL) response against CD20-expressing tumor B cells.
- Specifications
- Detects human CD3/CD20. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Mosunetuzumab.
- Product Name Alternative
- BTCT4465A
- UniProt
- P07766
- Species Reactivity
- Human
- Target
- CD3e + CD20
- Isotype
- IgG1
- Applications
- Functional Assays
- Purification Method
- This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
- Concentration
- 5mg/mL
- Endotoxin
- ≤ 1.0 EU/mg as determined by the LAL method
- Purity
- >90% by SDS-PAGE
- Buffer
- ICH3002
- Shipping Conditions
- Blue ice
- Storage Conditions
- This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.
- Formulation
- Sterile, preservative-free, solution in PBS. BSA and Azide free.
- Applications Notes
- This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.
- Isotype Control
- https://ichor.bio/product/bulk-human-igg1-isotype-control-ib1-ich2254/